21 |
MANIPULATING DYNAMIC ASTROCYTE FUNCTION DURING CUPRIZONE TREATMENT: CO-TREATMENT WITH COMPLEMENT RECEPTOR INHIBITORFrankle, Lana 27 April 2023 (has links)
No description available.
|
22 |
Evaluation of neurochemical and functional effects of glial cell-derived neurotrophic factor gene delivery using a tetracycline-regulatable adeno-associated viral vectorYang, Xin 24 June 2011 (has links)
Gene transfer to the brain is a promising therapeutic strategy for a variety of neurodegenerative disorders including Parkinson‟s disease (PD). PD is the second most common neurodegenerative disease. Although many drugs have been developed and introduced into the market to provide symptomatic treatment, there is still no cure for PD. Glial cell line-derived neurotrophic factor (GDNF) is a potent survival factor for injured nigrostriatal dopamine neurons and is currently being evaluated as a potential treatment for PD. Gene therapy allows localized, long-term and stable transgene expression after a single intervention to obtain a therapeutic effect. Regulatable promoters for transgene expression furthermore allow optimizing GDNF concentration to avoid undesirable biological activity and clinical side effects. In the first part of the study, an autoregulatory tetracycline-inducible recombinant adeno-associated viral vector (rAAV-pTetbidiON) utilizing the rtTAM2 reverse tetracycline transactivator (rAAV-rtTAM2) was used to conditionally express the human GDNF cDNA. Eight weeks after a single intrastriatal injection of the rAAV-rtTAM2-GDNF vector encapsidated into AAV serotype 1 capsids (rAAV2/1), the GDNF protein level was respectively 15 fold higherand undistinguishable from the endogenous level in doxycycline(Dox) treated and untreated animals. However, a residual GDNF expression in the uninduced animals was evidenced by a sensitive immunohistochemical staining. As compared to rAAV2/1-rtTAM2-GDNF, the rAAV2/1-rtTAM2-WPRE-GDNF vector harboring a woodchuck hepatitis post-transcriptional regulatory element, which increases and stabilizes the transgene transcript, expressed a similar concentration of GDNF in the induced state but a basal level ~2.5-fold higher than the endogenous striatal level. However, the distribution of GDNF in the striatum in induced state was more widespread using the rAAV2/1-rtTAM2-WPRE-GDNF vector as compared to rAAV2/1-rtTAM2- GDNF. As a proof for biological activity, for both vectors, downregulation of tyrosine hydroxylase (TH) was evidenced in dopaminergic terminals of Dox-treated but not untreated animals. In the second part of my study, functional (behavioural) and neurochemical changes mediated by delayed intrastriatal GDNF gene delivery in the partial Parkinson‟s disease rat model were investigated. The rAAV2/1-rtTAM2-WPRE-GDNF vector (3.5 108 viral genomes) was administered unilaterally in the rat striatum 5 weeks after intrastriatal injection of 6-hydroxydopamine (6-OHDA) which produces a partial and progressive lesion of the nigro-striatal dopaminergic pathway. Rats were treated with Dox or untreated from the day of vector injection until sacrifice at 4 or 14 weeks (continuous treatment). A sub-group was Dox-treated for 7 weeks (temporary treatment) then untreated until 14 weeks. In the absence of Dox, the GDNF tissue concentration was found to be equivalent to the endogenous level in 6-OHDA-lesioned rats. In the presence of Dox, it was ~10-fold higher. Dox-dependent behavioral improvements were demonstrated 4 weeks post-vector injection. At later time points, spontaneous partial recovery was observed in all rats, but no further improvement was found in Dox-treated animals. Moreover GDNF gene delivery only transiently improved dopaminergic function. Over the long term, TH was more abundant, but not functional, and the increase was lost when GDNF gene expression was switched off. The third part of my study consisted in the evaluation of the respective dose-range of therapeutical and undesirable effects of GDNF. Functional effects appeared after delivery of 3.5 108 viral particles which produced 200-300 pg/mg protein of GDNF in the lesioned rat striatum (see above). In order to evaluate the viral dose producing undesirable effects, we compared two different doses of vector: 3.5x108 and 4.4x109 viral genome. In the low dose group, the GDNF concentration in the striatum was ~300 pg/mg protein in the Dox-treated animals and equivalent to the endogenous level in untreated animals (~20 pg/mg protein). In contrast, in the high dose group, GDNF levels reached ~1200 pg/mg protein in induced animals but up to ~300 pg/mg protein in uniduced animals. In the low dose group, Dox-dependent downregulation of TH but no asymetrical behaviour was evidenced. In the high dose group, TH downregulation was observed in both Dox+ and Dox-rats. In addition, amphetamine-induced rotational behaviour was evidenced in Dox+ but not in Dox-rats. These data suggest that low doses of virus are sufficient to induce therapeutically-relevant but not undesirable functional effects of GDNF. Nevertheless,a neurochemical effect of GDNF (TH down-regulation) did appear at low dose. In order to understand the GDNF-induced motor asymmetry, we investigated the anatomical pattern of TH down regulation in striatum. Strikingly, there was a greater loss of TH labeling in striosomes than in the surrounding matrix. Receptors which are known to be differentially expressed in the striosomes i.e. µ-opioid receptor(MOR-1) and N-methyl-D-aspartic acid (NMDA) receptor 1 (NR1) as compared to the matrix were analyzed in the high-dose group of animals. MOR-1 was not affected by GDNF gene delivery. In contrast, NR1 was down regulated. The potential relationship between TH and NR1 down-regulation as well as other previously described neurochemical effects of GDNF (as enhancement of DA release and metabolism, of DA neurons excitability or of TH phosphorylation) and behavioural asymmetry remains to be clarified. As summary, our data suggest that behavioural and neurochemical effects of striatal delivery of GDNF can be controlled by Dox by using the autoregulatory rAAV2/1-TetON- GDNF vector, provided the dose range of gene delivery is carefully adjusted. / Doctorat en Sciences biomédicales et pharmaceutiques / info:eu-repo/semantics/nonPublished
|
23 |
Buněčné složení mozku rypošů (Bathyergidae): Data pro testování hypotézy sociálního mozku / Brains of African mole-rats in numbers: Data for testing the social brain hypothesisKverková, Kristina January 2016 (has links)
The social brain hypothesis (SBH) posits that complex social environments exert a major selection pressure driving the evolution of large brains and intelligence. The hypothesis was first proposed to explain the remarkable cognitive abilities of primates and has since been extended to other vertebrate groups and gained a substantial popularity. Nevertheless, the empirical support is equivocal in virtually every group where the hypothesis has been tested. In this thesis, the SBH is tested in the African mole-rats (Bathyergidae). Mole-rats share a subterranean mode of life and similar ecologies while covering the whole social spectrum, from solitary to "eusocial". The number of brain neurons is considered a better proxy for intelligence than relative or absolute brain size. Therefore, a novel approach, the isotropic fractionator, was used to estimate the total number of neurons and other cells in five brain parts (olfactory bulbs, cerebral cortex, cerebellum, diencephalon and basal ganglia, brain stem) of eleven bathyergid species. This simultaneously allows for examining if and how mole-rats differ from other rodents with respect to brain cellular scaling rules. We found that, contrary to expectations, mole-rats generally conform to these rules, with a few exceptions. They tend to have higher...
|
24 |
Caractérisation de la jonction neuromusculaire au cours du vieillissement chez l’humainMarchand, Sandrine 02 1900 (has links)
Le vieillissement entraîne plusieurs changements au niveau de la fonction musculaire qui peuvent mener à une perte de la masse musculaire et de sa fonction qu’on appelle sarcopénie. La sarcopénie entraîne une augmentation du risque de chutes et d’hospitalisations qui nuit à la qualité de vie des personnes âgées. Le vieillissement de la population représente un enjeu important au sein de la société en raison de son impact socioéconomique élevé. Plusieurs facteurs contribuent à ce déclin observé au cours du vieillissement, mais un des éléments clés qui y contribue sont des altérations de la jonction neuromusculaire (JNM). La JNM est une synapse tripartite composée de la terminaison nerveuse présynaptique, de la fibre musculaire postsynaptique et des cellules de Schwann périsynaptiques (CSPs), des cellules gliales. Les CSPs jouent un rôle essentiel dans la maintenance, la modulation de la transmission et de la plasticité synaptique et la réparation de la JNM. Plusieurs études effectuées chez le murin ont démontré que la JNM présente des altérations telles que de la dénervation, de la fragmentation du postsynaptique et des signes de modulation et de réparation gliaux au cours du vieillissement. Ces altérations contribuent aux déficits de la fonction neuromusculaire observés lors du vieillissement. La JNM humaine demeure cependant sous-étudiée, particulièrement en considérant sa structure tripartite. Afin de mieux comprendre le vieillissement neuromusculaire chez l’humain, des biopsies du Vastus lateralis ont été effectuées chez 4 jeunes adultes (23-28 ans) et 5 personnes âgées (60-75 ans) sains et actifs. Un marquage immunohistochimique a été effectué sur les biopsies afin d’identifier les trois composantes de base de la JNM et le type de fibre, puis visualiser en microscopie confocale. Des mesures fonctionnelles ont également été prélevées pour chacun des participants âgés. L’analyse des JNMs a permis de démontrer qu’une instabilité de l’innervation de même qu’une relation tripartite divergente se développe avec l’âge. Ces altérations corrèlent également avec un déficit fonctionnel. Dans l’ensemble, notre étude présente des altérations de la JNM humaine au cours du vieillissement ayant un impact sur la fonction neuromusculaire. Elle pourrait permettre de mieux comprendre les mécanismes à la base du vieillissement neuromusculaire pour développer des stratégies d’intervention thérapeutiques efficaces pour limiter l’impact du vieillissement. / Several changes occur in muscular function in aging which can lead to a loss of muscle mass and function called sarcopenia. Sarcopenia can lead to an increased risk of fall and hospitalization and to a poor quality of life. Aging of the population represents an important societal issue due to its high socioeconomic impact. Many factors contribute to the decline of muscular function seen in aging, but alterations of the neuromuscular junctions are a key element leading to sarcopenia. The NMJ is a tripartite synapse composed of the presynaptic nerve terminal, the postsynaptic muscle fiber as well as perisynaptic Schwann cells (PSC), glial cells. PSCs play a key role in maintenance, modulation of synaptic transmission and plasticity as well as repair of the NMJ. Several rodent studies have shown that the NMJ present alterations such as denervation, fragmentation of the postsynaptic and glial-related signs of modulation and repair in aging. These alterations contribute to the neuromuscular deficits observed in aging. However, the NMJ remain widely understudied, particularly when considering its tripartite structure. In order to get a better understanding of neuromuscular aging in humans, biopsies form the Vastus lateralis were performed on 4 young (23-28 years old) and 5 older (60-75 years old) healthy and physically active men. Immunohistochemistry labelling of the NMJ’s main components and type of fibers was performed and then imaged using confocal microscopy. Functional assessment was also measured for each older adult. Analysis of NMJs revealed an instability in the innervation as well as a divergent tripartite relationship in older individuals. These alterations also correlated with neuromuscular deficits. Taken altogether, our study highlights alterations of the NMJ in aging leading to altered neuromuscular function. This could lead to a better understanding of the underlying mechanisms leading to sarcopenia and to develop better therapeutic strategies to limit its impact during aging.
|
25 |
On pathophysiological mechanisms in amyothrophic lateral sclerosisGrundström, Eva January 2000 (has links)
<p>Amyotrophic lateral sclerosis is a fatal, progressive neurodegenerative disease with unknown ethiology. The aim of this study was to increase understanding of the pathophysiological mechanisms of dying motor neurons and wasting muscle tissue in this particular disorder.</p><p>Quantitative receptor autoradiographic methodology was applied on cervical spinal cord sections from patients with ALS to evaluate the specific binding of the acetylcholine transporter <sup>3</sup>H-vesamicol in motor neurons. Despite a significant reduction of the number of ventral motor neurons in ALS, the <sup>3</sup>H-vesamicol binding was not reduced in ALS compared to control cases, which suggests an increased metabolic activity in remaining motor neurons.</p><p>Motor neurons dying in ALS might go through apoptosis (programmed cell death), so immunohistochemical and TUNEL techniques were applied on thoracic spinal cord from ALS patients to evaluate the possibility of an apoptotic process. The increased Bax expression indicates an apoptotic process and further, motor neurons were TUNEL-positive, indicating DNA degradation caused by programmed cell death.</p><p>Muscle biopsies were obtained from ALS patients, and mRNA levels for the neurotrophic factors GDNF and BDNF were measured and compared to control subjects. GDNF levels were increased in muscle tissue in ALS whereas BDNF levels were unaltered.</p><p>Levels of GDNF and BDNF were also measured in cerebrospinal fluid from ALS patients and controls using ELISA methodology. Levels of BDNF were unaltered in ALS cornpared to controls. GDNF however was not detectable in controls whereas 12 out of 15 ALS patients had measurab1e levels of GDNW. A marked upregulation of endogenous GDNF and GDNF mRNA in ALS CSF and muscle respectively is of special interest in relation to clinical trials where GDNF is administered to this group of patients.</p>
|
26 |
On pathophysiological mechanisms in amyothrophic lateral sclerosisGrundström, Eva January 2000 (has links)
Amyotrophic lateral sclerosis is a fatal, progressive neurodegenerative disease with unknown ethiology. The aim of this study was to increase understanding of the pathophysiological mechanisms of dying motor neurons and wasting muscle tissue in this particular disorder. Quantitative receptor autoradiographic methodology was applied on cervical spinal cord sections from patients with ALS to evaluate the specific binding of the acetylcholine transporter 3H-vesamicol in motor neurons. Despite a significant reduction of the number of ventral motor neurons in ALS, the 3H-vesamicol binding was not reduced in ALS compared to control cases, which suggests an increased metabolic activity in remaining motor neurons. Motor neurons dying in ALS might go through apoptosis (programmed cell death), so immunohistochemical and TUNEL techniques were applied on thoracic spinal cord from ALS patients to evaluate the possibility of an apoptotic process. The increased Bax expression indicates an apoptotic process and further, motor neurons were TUNEL-positive, indicating DNA degradation caused by programmed cell death. Muscle biopsies were obtained from ALS patients, and mRNA levels for the neurotrophic factors GDNF and BDNF were measured and compared to control subjects. GDNF levels were increased in muscle tissue in ALS whereas BDNF levels were unaltered. Levels of GDNF and BDNF were also measured in cerebrospinal fluid from ALS patients and controls using ELISA methodology. Levels of BDNF were unaltered in ALS cornpared to controls. GDNF however was not detectable in controls whereas 12 out of 15 ALS patients had measurab1e levels of GDNW. A marked upregulation of endogenous GDNF and GDNF mRNA in ALS CSF and muscle respectively is of special interest in relation to clinical trials where GDNF is administered to this group of patients.
|
27 |
Cellular Origin and Development of GliomaLindberg, Nanna January 2009 (has links)
Gliomas are the most common primary tumors of the central nervous system believed to arise from glial cells. Invasive growth and inherent propensity for malignant progression make gliomas incurable despite extensive treatment. I have developed a life-like orthotopic glioma model and used this and other in vivo models to study basic mechanisms of glioma development and treatment. Previous studies had indicated that experimental gliomas could arise from glial stem cells and astrocytes. The present thesis describes the making and characterization of a novel mouse model, Ctv-a, where gliomas are induced from oligodendrocyte progenitor cells (OPCs). Our study shows that OPCs have the capacity to give rise to gliomas and suggests in light of previous data that the differentiation state of the cell of origin affects tumor malignancy. CDKN2A encodes p16INK4a and p14ARF (p19Arf in mouse) commonly inactivated in malignant glioma. Their roles in experimental glioma have been extensively studied and both proteins have tumor suppressor functions in glial stem cells and astrocytes. Here, we demonstrate that p19Arf only could suppress gliomagenesis in OPCs while p16Ink4a had no tumor suppressive effect. Functional DNA repair is pivotal for maintaining genome integrity, eliminating unsalvageable cells and inhibiting tumorigenesis. We have studied how RAD51, a central protein of homology-directed repair, affected experimental glioma development and have found that expression of RAD51 may protect against genomic instability and tumor development. Angiogenesis, the formation of new blood vessels from pre-existing ones, is a central feature of malignant progression in glioma. Antiangiogenic treatment by inhibition of vascular endothelial growth factor receptor signaling is used in the clinic for treatment of some cancers. We have investigated the effect of an alternative antiangiogenic protein, histidine-rich glycoprotein (HRG), on glioma development and found that HRG could inhibit the formation of malignant gliomas and completely prevent the formation of glioblastoma.
|
Page generated in 0.0729 seconds